Rhythm Pharmaceuticals, Inc.'s SEC filings document a commercial-stage biopharmaceutical company whose disclosures center on IMCIVREE (setmelanotide), MC4R pathway rare-disease indications and related clinical and regulatory milestones. Recent Form 8-K reports include operating results, product-revenue commentary, FDA and European regulatory updates for acquired hypothalamic obesity, and trial disclosures for programs such as TRANSCEND and EMANATE.
Rhythm's proxy materials and governance filings disclose board composition, director elections, executive compensation, equity awards and shareholder voting matters. Other current reports record director changes, Regulation FD materials, presentations and press releases, tying corporate governance and public-company reporting to the company's rare neuroendocrine disease portfolio.
Rhythm Pharmaceuticals, Inc. (RYTM) – Form 4 insider filing dated 06/23/2025
Director David W. J. McGirr reported the vesting and settlement of 4,000 Restricted Stock Units (RSUs) on June 18, 2025 (Transaction Code M). Each RSU converted into one share of common stock at an exercise price of $0.00, resulting in the direct acquisition of 4,000 shares. Following the transaction, McGirr’s direct beneficial ownership in Rhythm Pharmaceuticals increased to 7,000 common shares. The filing shows no open-market purchase or sale and leaves McGirr with no remaining derivative securities tied to this award.
The RSUs fully vested on the same date and carry no expiration. Because the transaction reflects routine equity compensation rather than discretionary share purchases or sales, the economic impact on Rhythm Pharmaceuticals is limited, but it modestly aligns the director’s incentives with shareholder interests.
Rhythm Pharmaceuticals, Inc. (RYTM) – Form 4 insider filing
Director Lynn A. Tetrault reported the vesting and automatic conversion of 4,000 restricted stock units (RSUs) into an equal number of common shares on 18 Jun 2025 (transaction code M). No shares were sold, transferred, or otherwise disposed of, and the transaction was completed at a conversion price of $0.00, as RSUs carry no cash exercise cost.
Following the transaction, Tetrault’s direct beneficial ownership increased to 7,000 common shares. The RSUs had fully vested on the same date and do not carry an expiration date, indicating they were part of a previously granted equity incentive award. The filing contains no open-market purchases, option exercises for cash, or sales, and therefore does not create immediate cash proceeds for the insider or raise additional capital for the company.
Investor takeaway: The director’s decision to retain the newly issued shares rather than sell them marginally aligns insider interests with shareholders but is routine for RSU vesting events and is not large enough to materially affect share count or signal a strong directional view on RYTM’s valuation.